KalshiVérifier la disponibilitéKYC requis2% de fraisDonnées de résolution vérifiéesGrossièrement calibréProbabilité implicite actuelleBefore Jan 1, 2031 56%En tête parmi 6 options
Qualite du marche
40 / 100
Faible qualitéVolume 24h
0 €
Liquidité
1,3 k €
Faible liquiditéAchat / Vente
11.0% / 16.0%
Spread
5.0 pt
Spread modéréDonnées du marché
Mis à jour il y a 16 minutes
14 mai 26, 2:001 janv. 27, 4:59
Tendances
Fonds fictifs uniquement, aucun argent réelCeci n'est pas un conseil financier
Résultat choisi
Before Jan 1, 202710%
Tendance du volume
$22 juil.10j de données27 juil.
Marchés Associés
Will the FDA approve camizestrant for advanced breast cancer?
47 €Before Oct 1, 2026: 37%KALSHI
KALSHI
Hantavirus pandemic in 2026?
92,6 k €Oui: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
7,6 k €26-27M: 89%POLYMARKET
POLYMARKET
New pandemic in 2026?
5 k €Oui: 9%POLYMARKET
POLYMARKET
Measles cases in 2026?
2,4 k €Above 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
2,1 k €Oui: 5%KALSHI
KALSHIActifs dans ces sujets
Règles
If the FDA approves midomafetamine / MDMA for PTSD for marketing before Jan 1, 2027, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: